Jalra-M 50mg/1000mg Tablet is a fixed-dose combination medication containing Metformin hydrochloride 1000mg and Vildagliptin 50mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, thereby enhancing glucose uptake and utilization. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases the levels of incretin hormones, which stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner. The combination of these agents provides complementary mechanisms to achieve better glycemic control in patients inadequately controlled on monotherapy or lifestyle interventions. Jalra-M is typically prescribed as an adjunct to diet and exercise to improve glycemic parameters such as fasting plasma glucose and HbA1c. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal impairment, or known hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances, headache, and nasopharyngitis, while rare but serious risks include lactic acidosis and pancreatitis. Regular monitoring of renal function and glycemic status is recommended during therapy. Jalra-M should be used under medical supervision with appropriate dose adjustments based on clinical response and tolerability.